Livanova Plc OR Sh (LIVN) Stock Price, Quote & News

Company Profile

LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygena...

Industry: Medical Devices

Sector: Healthcare

Phone: 44 20 3325 0660

Website: www.livanova.com

Address:

20 Eastbourne Terrace, London, United Kingdom

BillionerOfKing May. 11 at 4:54 PM

$LIVN Current Stock Price: $70.43 Contracts to trade: $70.0 LIVN May 15 2026 Call Entry: $1.25 Exit: $1.79 ROI: 43% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

SmartMoneyTradez May. 7 at 7:33 PM

$ACMR $LIVN

0 · Reply

Mogeyman May. 7 at 6:30 PM

$LIVN

0 · Reply

The_Gambl3r May. 7 at 3:09 AM

$LIVN $MDT $FMS $BAX $NUWE ** 👀👀

1 · Reply

Estimize May. 6 at 10:06 PM

$LIVN reported 0.98 EPS and 263.30 revenue for Q1. http://www.estimize.com/intro/livn?chart=historical&metric_name=eps&utm_content=LIVN&utm

0 · Reply

StocktwitsEarnings May. 6 at 10:17 AM

$LIVN Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $0.41 up 106.82% YoY • Reported revenue of $362.3M up 14.34% YoY • LivaNova raised its full-year 2026 constant-currency revenue growth guidance to 7.0% to 8.0% and adjusted diluted EPS to $4.20 to $4.30, while maintaining adjusted free cash flow guidance at $160M to $180M.

0 · Reply

Estimize May. 4 at 10:03 AM

Wall St is expecting 0.90 EPS for $LIVN Q1 [Reporting 05/06 BMO] http://www.estimize.com/intro/livn?chart=historical&metric_name=eps&utm_co

0 · Reply

OfficialStocktwitsUser May. 1 at 4:52 PM

$LIVN RSI: 34.86, MACD: -0.8246 Vol: 2.08, MA20: 63.68, MA50: 64.16 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

BillionerOfKing Mar. 3 at 2:37 AM

$LIVN Current Stock Price: $70.26 Contracts to trade: $70.0 LIVN Mar 20 2026 Call Entry: $0.95 Exit: $1.53 ROI: 61% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

OfficialStocktwitsUser Feb. 26 at 8:33 PM

$LIVN RSI: 72.90, MACD: 1.6213 Vol: 1.86, MA20: 66.92, MA50: 64.57 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

LivaNova price target lowered to $76 from $78 at Baird

2026-05-07T15:50:20.000Z - 5 days ago

LivaNova price target raised to $90 from $85 at Mizuho

2026-05-07T11:56:34.000Z - 6 days ago

LivaNova price target raised to $76 from $73 at Barclays

2026-05-07T09:56:32.000Z - 6 days ago

LivaNova reports Q1 adjusted EPS 98c, consensus 90c

2026-05-07T09:55:47.000Z - 6 days ago

LivaNova raises FY26 adjusted EPS view to $4.20-$4.30 from $4.15-$4.25

May 6, 2026, 8:00 AM EDT - 7 days ago

LivaNova Earnings Call Transcript: Q1 2026

May 6, 2026, 6:00 AM EDT - 7 days ago

LivaNova Reports First-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance

Apr 20, 2026, 5:05 PM EDT - 22 days ago

Annals of Internal Medicine Publishes 12-Month Results from LivaNova's OSPREY Clinical Study for Obstructive Sleep Apnea

Mar 25, 2026, 9:00 AM EDT - 6 weeks ago

LivaNova to Announce First-Quarter 2026 Results

2026-03-19T12:42:05.000Z - 7 weeks ago

LivaNova granted premarket approval for aura6000 System by FDA

Mar 19, 2026, 8:30 AM EDT - 7 weeks ago

LivaNova Receives U.S. Food and Drug Administration Premarket Approval for aura6000 System to treat Moderate to Severe Obstructive Sleep Apnea

2026-02-27T10:40:15.000Z - 2 months ago

LivaNova price target raised to $73 from $67 at Barclays

2026-02-26T15:21:58.000Z - 2 months ago

LivaNova price target raised to $83 from $75 at Baird

2026-02-26T14:36:44.000Z - 2 months ago

LivaNova price target raised to $85 from $72 at Mizuho

2026-02-26T11:55:03.000Z - 2 months ago

LivaNova price target raised to $73 from $66 at Goldman Sachs

2026-02-25T20:55:33.000Z - 2 months ago

LivaNova price target raised to $80 from $70 at Stifel

Feb 25, 2026, 8:00 AM EST - 2 months ago

LivaNova Earnings Call Transcript: Q4 2025

2026-02-25T11:12:16.000Z - 2 months ago

LivaNova sees FY26 adjusted EPS $4.15-$4.25, consensus $4.13

2026-02-25T11:05:32.000Z - 2 months ago

LivaNova reports Q4 djusted EPS 86c, consensus 81c

Feb 25, 2026, 6:00 AM EST - 2 months ago

LivaNova Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Guidance

Jan 20, 2026, 9:00 AM EST - 4 months ago

LivaNova to Announce Fourth-Quarter and Full-Year 2025 Results

Jan 14, 2026, 4:30 PM EST - 4 months ago

LivaNova Transcript: 44th Annual J.P. Morgan Healthcare Conference

2026-01-09T12:25:56.000Z - 4 months ago

LivaNova price target raised to $67 from $58 at Barclays

2026-01-09T10:56:04.000Z - 4 months ago

LivaNova price target raised to $66 from $56 at Goldman Sachs

2026-01-07T12:41:34.000Z - 4 months ago

LivaNova price target raised to $70 from $65 at Stifel

Dec 23, 2025, 9:00 AM EST - 5 months ago

LivaNova to Present at J.P. Morgan Healthcare Conference in January

2025-12-19T09:45:18.000Z - 5 months ago

KeyBanc starts LivaNova at Overweight on estimate upside potential

2025-12-19T01:05:08.000Z - 5 months ago

LivaNova initiated with an Overweight at KeyBanc

2025-12-17T12:01:22.000Z - 5 months ago

LivaNova price target raised to $72 from $70 at Mizuho

2025-12-16T10:40:55.000Z - 5 months ago

LivaNova price target raised to $75 from $70 at Baird

Dec 3, 2025, 9:00 AM EST - 5 months ago

LivaNova to Highlight Real-World Evidence from CORE-VNS Study and New Health Economics Analyses at American Epilepsy Society 2025 Annual Meeting

Dec 2, 2025, 1:30 PM EST - 5 months ago

LivaNova Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 2, 2025, 9:00 AM EST - 5 months ago

LivaNova Appoints Lucile Blaise as Global Head of Commercialization, Obstructive Sleep Apnea

Nov 25, 2025, 9:00 AM EST - 6 months ago

LivaNova to Present at Piper Sandler Healthcare Conference in December

Nov 24, 2025, 9:00 AM EST - 6 months ago

LivaNova's VNS Therapy for Drug-Resistant Epilepsy Procedures Receives Increased Provider Reimbursement from U.S. Centers for Medicare & Medicaid Services

Nov 17, 2025, 2:40 PM EST - 6 months ago

LivaNova Transcript: Wolfe Research Healthcare Conference 2025

Nov 12, 2025, 3:26 PM EST - 6 months ago

LivaNova Delivers Strategic Roadmap and Long-Range Financial Plan at Investor Day

Nov 12, 2025, 9:00 AM EST - 6 months ago

LivaNova Transcript: Investor Day 2025

Nov 5, 2025, 8:00 AM EST - 6 months ago

LivaNova Earnings Call Transcript: Q3 2025

Nov 5, 2025, 6:00 AM EST - 6 months ago

LivaNova Reports Third-Quarter 2025 Results; Raises 2025 Guidance

Oct 23, 2025, 9:00 AM EDT - 7 months ago

LivaNova to Present at Wolfe Research Healthcare Conference in November

Oct 8, 2025, 9:00 AM EDT - 7 months ago

LivaNova to Announce Third-Quarter 2025 Results

Oct 7, 2025, 9:00 AM EDT - 7 months ago

LivaNova to Present Scientific Data at International Surgical Sleep Society 2025 Annual Meeting

Sep 10, 2025, 1:05 PM EDT - 8 months ago

LivaNova Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 9, 2025, 3:45 PM EDT - 8 months ago

LivaNova Transcript: Baird Global Healthcare Conference 2025

Sep 4, 2025, 9:00 AM EDT - 8 months ago

LivaNova Appoints Donald Zurbay as a New Director

Aug 25, 2025, 9:00 AM EDT - 9 months ago

LivaNova to Host Investor Day on November 12, 2025

Aug 22, 2025, 9:00 AM EDT - 9 months ago

LivaNova to Present at Baird and Morgan Stanley Global Healthcare Conferences in September

Aug 18, 2025, 9:00 AM EDT - 9 months ago

LivaNova Launches Essenz Perfusion System in China

Aug 6, 2025, 8:00 AM EDT - 10 months ago

LivaNova Earnings Call Transcript: Q2 2025

Aug 6, 2025, 6:00 AM EDT - 10 months ago

LivaNova Reports Second-Quarter 2025 Results; Raises 2025 Guidance

Jul 9, 2025, 9:00 AM EDT - 10 months ago

LivaNova to Announce Second-Quarter 2025 Results

Jun 11, 2025, 10:00 AM EDT - 11 months ago

LivaNova Transcript: AGM 2025

Jun 5, 2025, 3:10 PM EDT - 1 year ago

LivaNova Transcript: Jefferies Global Healthcare Conference 2025

Jun 5, 2025, 8:15 AM EDT - 1 year ago

CORE-VNS Study Further Validates Effectiveness of LivaNova's VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant Epilepsy

Jun 5, 2025, 8:00 AM EDT - 1 year ago

LivaNova Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy

Jun 4, 2025, 8:00 AM EDT - 1 year ago

LivaNova Initiates Process with U.S. Centers for Medicare and Medicaid Services for Reconsideration of National Coverage for VNS Therapy for Treatment-Resistant Depression

May 15, 2025, 8:00 AM EDT - 1 year ago

LivaNova to Present at the Jefferies Global Healthcare Conference

May 7, 2025, 8:00 AM EDT - 1 year ago

LivaNova Earnings Call Transcript: Q1 2025

May 7, 2025, 6:00 AM EDT - 1 year ago

LivaNova Reports First-Quarter 2025 Results; Updates 2025 Guidance

May 7, 2025, 5:45 AM EDT - 1 year ago

LivaNova Announces 12-month Data from OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea, Demonstrating Strong Response and Durability of Therapy

Mar 26, 2025, 8:00 AM EDT - 1 year ago

LivaNova to Announce First-Quarter 2025 Results

Mar 11, 2025, 2:00 PM EDT - 1 year ago

LivaNova Transcript: Barclays 27th Annual Global Healthcare Conference

Feb 25, 2025, 8:00 AM EST - 1 year ago

LivaNova Earnings Call Transcript: Q4 2024

Feb 25, 2025, 6:00 AM EST - 1 year ago

LivaNova Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Guidance

Feb 21, 2025, 9:00 AM EST - 1 year ago

LivaNova to Present at the Barclays Global Healthcare Conference

Jan 21, 2025, 9:00 AM EST - 1 year ago

LivaNova to Announce Fourth-Quarter and Full-Year 2024 Results

Dec 18, 2024, 8:30 AM EST - 1 year ago

RECOVER Clinical Study Shows Meaningful Benefits of LivaNova's VNS Therapy System in Select Secondary Endpoints for Unipolar Patients with Treatment-Resistant Depression

Dec 5, 2024, 9:00 AM EST - 1 year ago

LivaNova to Present Scientific Data at American Epilepsy Society 2024 Annual Meeting

Dec 3, 2024, 10:00 AM EST - 1 year ago

LivaNova Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 20, 2024, 1:20 PM EST - 1 year ago

LivaNova Transcript: Wolfe Research 2024 Healthcare Conference

Nov 19, 2024, 11:30 AM EST - 1 year ago

LivaNova Transcript: Stifel 2024 Healthcare Conference

Nov 14, 2024, 9:00 AM EST - 1 year ago

LivaNova to Present at the Stifel, Wolfe, and Piper Sandler Healthcare Conferences

Nov 11, 2024, 4:05 PM EST - 1 year ago

LivaNova Announces OSPREY Clinical Study Meets Primary Safety and Efficacy Endpoints

Oct 30, 2024, 8:00 AM EDT - 1 year ago

LivaNova Earnings Call Transcript: Q3 2024

Oct 30, 2024, 6:00 AM EDT - 1 year ago

LivaNova Reports Third-Quarter 2024 Results

Oct 8, 2024, 9:00 AM EDT - 1 year ago

LivaNova Appoints Susan Podlogar as a New Director

Sep 25, 2024, 9:00 AM EDT - 1 year ago

LivaNova to Announce Third-Quarter 2024 Results

Sep 10, 2024, 10:15 AM EDT - 1 year ago

LivaNova Transcript: Baird 2024 Global Healthcare Conference

Aug 19, 2024, 9:00 AM EDT - 1 year ago

LivaNova to Present at the Baird Global Healthcare Conference

Jul 31, 2024, 8:00 AM EDT - 1 year ago

LivaNova Earnings Call Transcript: Q2 2024

Jul 31, 2024, 6:00 AM EDT - 1 year ago

LivaNova Reports Second-Quarter 2024 Results

Jun 24, 2024, 6:24 PM EDT - 2 years ago

Federman & Sherwood Investigates LivaNova USA, Inc. for Data Breach

Jun 18, 2024, 9:00 AM EDT - 2 years ago

LivaNova to Announce Second-Quarter 2024 Results

Jun 11, 2024, 10:00 AM EDT - 2 years ago

LivaNova Transcript: AGM 2024

Jun 10, 2024, 1:20 PM EDT - 2 years ago

LivaNova Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 6, 2024, 9:00 AM EDT - 2 years ago

LivaNova Provides Update on RECOVER Clinical Study Evaluating VNS Therapy for Treatment-Resistant Depression in Unipolar Patients

May 23, 2024, 9:00 AM EDT - 2 years ago

LivaNova to Present at the Goldman Sachs Healthcare Conference

May 1, 2024, 8:00 AM EDT - 2 years ago

LivaNova Earnings Call Transcript: Q1 2024

May 1, 2024, 6:00 AM EDT - 2 years ago

LivaNova Reports First-Quarter 2024 Results

Apr 30, 2024, 9:00 AM EDT - 2 years ago

LivaNova Announces Ahmet Tezel, Ph.D., as Chief Innovation Officer

Apr 25, 2024, 4:03 PM EDT - 2 years ago

LivaNova Issues Notice to U.S. Patients Regarding Cybersecurity Incident

BillionerOfKing May. 11 at 4:54 PM

0 · Reply

SmartMoneyTradez May. 7 at 7:33 PM

$ACMR $LIVN

0 · Reply

Mogeyman May. 7 at 6:30 PM

$LIVN

0 · Reply

The_Gambl3r May. 7 at 3:09 AM

$LIVN $MDT $FMS $BAX $NUWE ** 👀👀

1 · Reply

Estimize May. 6 at 10:06 PM

$LIVN reported 0.98 EPS and 263.30 revenue for Q1. http://www.estimize.com/intro/livn?chart=historical&metric_name=eps&utm_content=LIVN&utm

0 · Reply

StocktwitsEarnings May. 6 at 10:17 AM

0 · Reply

Estimize May. 4 at 10:03 AM

Wall St is expecting 0.90 EPS for $LIVN Q1 [Reporting 05/06 BMO] http://www.estimize.com/intro/livn?chart=historical&metric_name=eps&utm_co

0 · Reply

OfficialStocktwitsUser May. 1 at 4:52 PM

0 · Reply

BillionerOfKing Mar. 3 at 2:37 AM

0 · Reply

OfficialStocktwitsUser Feb. 26 at 8:33 PM

0 · Reply

Estimize Feb. 25 at 11:09 PM

$LIVN reported 0.86 EPS and 360.90 revenue for Q4. http://www.estimize.com/intro/livn?chart=historical&metric_name=eps&utm_content=LIVN&utm

0 · Reply

briefingcom Feb. 25 at 1:12 PM

$LIVN: LivaNova beats by $0.04, beats on revs; guides FY26 EPS above consensus, revs in-line https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20260225061017LIVN&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

0 · Reply

StocktwitsEarnings Feb. 25 at 11:13 AM

$LIVN Q4 '25 Earnings Results & Recap • Reported GAAP EPS of $0.57 down -44.66% YoY • Reported revenue of $360.9M up 12.15% YoY • LivaNova PLC expects full-year 2026 revenue to grow 6.0% to 7.0% on a constant-currency basis. Adjusted diluted earnings per share is projected between $4.15 and $4.25, with adjusted free cash flow in the $160 million to $180 million range.

0 · Reply

CycleDriver Feb. 18 at 3:50 PM

$LIVN LivaNova operates medical devices with exposure to cardiac and neuromodulation markets. Growth depends on procedural volumes and innovation pipeline. Margin improvement supports long-term outlook.

0 · Reply

BillionerOfKing Jan. 27 at 8:20 PM

$LIVN Current Stock Price: $63.92 Contracts to trade: $65 LIVN Feb 20 2026 Call Entry: $1.75 Exit: $2.25 ROI: 28% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

JarvisFlow Dec. 19 at 12:03 PM

Keybanc updates rating for LivaNova ( $LIVN ) to Overweight, target set at 81.

0 · Reply

JarvisFlow Dec. 17 at 3:05 PM

Mizuho updates rating for LivaNova ( $LIVN ) to Outperform, target set at 70 → 72.

0 · Reply

BillionerOfKing Dec. 10 at 11:50 PM

$LIVN Current Stock Price: $64.06 Contracts to trade: $65 LIVN Dec 19 2025 Call Entry: $0.23 Exit: $0.31 ROI: 37% Hold ~25 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Estimize Nov. 27 at 11:00 AM

Wall St is expecting 0.81 EPS for $LIVN Q4 [Reporting 02/25 BMO] http://www.estimize.com/intro/livn?chart=historical&metric_name=eps&utm_co

0 · Reply

Market Cap	3.85B
Revenue (ttm)	1.39B
Net Income (ttm)	-242.47M
EPS (ttm)	N/A
PE Ratio	20.53
Forward PE	19.55
Profit Margin	-17.47%
Debt to Equity Ratio	0.24

Volume	1,019,300
Avg Vol	872,724
Day's Range	N/A - N/A
Shares Out	54.93M
Stochastic %K	94%
Beta	0.82
Analysts	Strong Sell
Price Target	$81.20